237 related articles for article (PubMed ID: 28439752)
1. Mathematical Modeling of Cellular Cross-Talk Between Endothelial and Tumor Cells Highlights Counterintuitive Effects of VEGF-Targeted Therapies.
Jain H; Jackson T
Bull Math Biol; 2018 May; 80(5):971-1016. PubMed ID: 28439752
[TBL] [Abstract][Full Text] [Related]
2. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
3. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
Tarallo V; De Falco S
Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Bender RJ; Mac Gabhann F
BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
[TBL] [Abstract][Full Text] [Related]
5. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
[TBL] [Abstract][Full Text] [Related]
6. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
de Aguiar RB; de Moraes JZ
Front Immunol; 2019; 10():1023. PubMed ID: 31156623
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
10. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
12. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
13. The direct effects of anti-vascular endothelial growth factor therapy on tumor cells.
Moser C; Lang SA; Stoeltzing O
Clin Colorectal Cancer; 2007 Jul; 6(8):564-71. PubMed ID: 17681102
[TBL] [Abstract][Full Text] [Related]
14. [VEGF and its receptors as therapeutic target in cancer therapy].
Gisterek I; Kornafel J
Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.
Gaddy TD; Wu Q; Arnheim AD; Finley SD
PLoS Comput Biol; 2017 Dec; 13(12):e1005874. PubMed ID: 29267273
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814
[TBL] [Abstract][Full Text] [Related]
18. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
19. Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development.
Lazarovici P; Marcinkiewicz C; Lelkes PI
Curr Pharm Des; 2006; 12(21):2609-22. PubMed ID: 16842161
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor receptors: expression and function in solid tumors.
Wey JS; Stoeltzing O; Ellis LM
Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
